Evaluation of immune response in calves vaccinated with baculovirus vectored inactivated vaccine expressing 2.3.4.4b H5 protein of highly pathogenic Avian Influenza virus

Clade 2.3.4.4b H5N1 highly pathogenic avian influenza (HPAI) virus is circulating widely in US dairy cattle with significant implications for milk production and cow health. Due to the critical need for intervention strategies for continuing outbreaks of bovine HPAI, a baculovirus vectored inactivated HPAI vaccine expressing the 2.3.4.4b H5 protein (Avian Influenza-H5) was developed utilizing a licensed prescription platform which has been tested and proven safe in multiple species. The immunogenicity of recombinant Avian Influenza-H5 vaccine was tested in 5-month-old calves. The subcutaneously vaccinated animals showed minor post-injection site swelling that resolved without further affect (or compromise). The vaccine induced a measurable immune response by ELISA 3 weeks after 1st vaccination although the antibody response was low or undetectable by virus neutralization (VN) or hemagglutination inhibition (HI) tests. Two- and four weeks after a 2nd vaccination, antibody titers greater than > 40, which are typically considered minimum protective titer against HPAI virus challenge, were consistently observed in all the vaccinated animals by both HI and VN tests. Strong correlation between VN and HI titers (Pearson correlation coefficient (r) greater than 0.8) were observed. Because the vaccine only contains the H5 protein of influenza virus, all vaccinated animals were negative against nucleoprotein (NP) and N1 neuraminidase antibody by commercial NP ELISA and N1 specific enzyme linked lectin assay, respectively, which confirm the vaccine is DIVA (differentiation of infected from vaccinated) surveillance compatible. In summary, this study demonstrates that an inactivated baculovirus-vectored vaccine, Avian Influenza-H5, is immunogenic and generates presumed protective antibody levels in calves, although future studies evaluating the vaccine in lactating dairy cattle would determine the induction of local immunity in the mammary gland and milk, and if the vaccine provides field protection against influenza-induced mastitis.

Authors

Institutions

Publication Details

Journal
Veterinary Microbiology
Published
2026-03-03
DOI
https://doi.org/10.1016/j.vetmic.2026.110970
Primary Topic
Virology and Viral Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of immune response in calves vaccinated with baculovirus vectored inactivated vaccine expressing 2.3.4.4b H5 protein of highly pathogenic Avian Influenza virus

Timothy L. Olivier, Alan J. Young, Sherry Glover, Bishwas Sharma et al.
Veterinary Microbiology
Virology and Viral Diseases
article

Evaluation of immune response in calves vaccinated with baculovirus vectored inactivated vaccine expressing 2.3.4.4b H5 protein of highly pathogenic Avian Influenza virus

Timothy L. Olivier, Alan J. Young, Sherry Glover, Bishwas Sharma, Amber Schueler, Bradley Gustafson, Sara Erickson, Youngsub Lee, Chang-Won Lee
article en

Abstract

Clade 2.3.4.4b H5N1 highly pathogenic avian influenza (HPAI) virus is circulating widely in US dairy cattle with significant implications for milk production and cow health. Due to the critical need for intervention strategies for continuing outbreaks of bovine HPAI, a baculovirus vectored inactivated HPAI vaccine expressing the 2.3.4.4b H5 protein (Avian Influenza-H5) was developed utilizing a licensed prescription platform which has been tested and proven safe in multiple species. The immunogenicity of recombinant Avian Influenza-H5 vaccine was tested in 5-month-old calves. The subcutaneously vaccinated animals showed minor post-injection site swelling that resolved without further affect (or compromise). The vaccine induced a measurable immune response by ELISA 3 weeks after 1st vaccination although the antibody response was low or undetectable by virus neutralization (VN) or hemagglutination inhibition (HI) tests. Two- and four weeks after a 2nd vaccination, antibody titers greater than > 40, which are typically considered minimum protective titer against HPAI virus challenge, were consistently observed in all the vaccinated animals by both HI and VN tests. Strong correlation between VN and HI titers (Pearson correlation coefficient (r) greater than 0.8) were observed. Because the vaccine only contains the H5 protein of influenza virus, all vaccinated animals were negative against nucleoprotein (NP) and N1 neuraminidase antibody by commercial NP ELISA and N1 specific enzyme linked lectin assay, respectively, which confirm the vaccine is DIVA (differentiation of infected from vaccinated) surveillance compatible. In summary, this study demonstrates that an inactivated baculovirus-vectored vaccine, Avian Influenza-H5, is immunogenic and generates presumed protective antibody levels in calves, although future studies evaluating the vaccine in lactating dairy cattle would determine the induction of local immunity in the mammary gland and milk, and if the vaccine provides field protection against influenza-induced mastitis.

Veterinary MicrobiologyVol. 316
Brookings Institution (US), Reprogenetics (US), U.S. National Poultry Research Center (US)
Good health and well-being
Openalex Percentile: Top 37%
Virology and Viral Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.